DiagnosticIn Clinical Trials

Bombesin Analog Tracers

Overview

Bombesin analog tracers are synthetic peptides based on the 14-amino acid amphibian peptide bombesin or its mammalian counterpart gastrin-releasing peptide (GRP), radiolabeled for molecular imaging. These analogs bind to GRP receptors, which are overexpressed in prostate, breast, and small cell lung cancers, enabling tumor visualization via PET or SPECT imaging. Various radionuclides including gallium-68, fluorine-18, technetium-99m, and copper-64 have been conjugated to bombesin antagonist and agonist peptides.

Key Research Findings

Phase 1 and Phase 2 clinical trials have evaluated multiple bombesin analogs including 68Ga-RM2, 68Ga-SB3, and 99mTc-DB4 for imaging prostate cancer and breast cancer, with results published in the Journal of Nuclear Medicine and European Journal of Nuclear Medicine between 2007 and 2020. While these agents demonstrate receptor-specific tumor uptake and acceptable safety, none have achieved regulatory approval, largely due to competition from PSMA-targeted tracers in prostate cancer imaging.

Route of Administration

Intravenous

Regulatory Status

In Clinical Trials

Interested in Bombesin Analog Tracers?

Find a verified provider experienced with Bombesin Analog Tracers protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Bombesin Analog Tracers Provider

Related Peptides

Pentagastrin

FDA Approved

A synthetic pentapeptide containing the C-terminal tetrapeptide sequence of gastrin (Trp-Met-Asp-Phe-NH2) linked to beta-alanine. Pentagastrin stimulates gastric acid secretion by binding to cholecystokinin-2 (CCK2) receptors on parietal cells, and stimulates calcitonin release from thyroid C-cells. It has been used as a diagnostic agent for both gastric acid secretory capacity testing and provocative testing for medullary thyroid carcinoma (MTC).

Gadopentetate Peptide Conjugates

Research Phase

Gadopentetate peptide conjugates consist of the gadolinium-based contrast agent gadopentetate dimeglumine chemically linked to targeting peptides designed to bind specific tissue markers or receptors. These hybrid molecules combine the MRI contrast properties of chelated gadolinium with the molecular specificity of peptides to enable targeted imaging of tumors, inflammatory lesions, or vascular pathology. Various peptide motifs including RGD sequences and somatostatin analogs have been conjugated to gadolinium chelates for preclinical evaluation.

DOTATATE (Ga-68)

FDA Approved

Gallium-68 DOTATATE is a radiolabeled somatostatin analog consisting of an octapeptide (Tyr3-octreotate) conjugated to the macrocyclic chelator DOTA, which binds the positron-emitting radioisotope gallium-68. It exhibits high affinity for somatostatin receptor subtype 2, which is overexpressed on neuroendocrine tumor cells, enabling PET imaging of these malignancies. The 68-minute half-life of gallium-68 and the rapid pharmacokinetics of the peptide provide excellent tumor-to-background ratios within 1 to 2 hours post-injection.

RGD Peptide Tracers

In Clinical Trials

RGD peptide tracers are short synthetic peptides containing the arginine-glycine-aspartic acid (RGD) tripeptide sequence, which binds to integrin receptors, particularly alphavbeta3, conjugated to positron or gamma-emitting radioisotopes. Alphavbeta3 integrin is upregulated on angiogenic endothelium and many cancer cells, making RGD tracers useful for imaging tumor angiogenesis, metastatic disease, and potentially cardiovascular pathology. Cyclic RGD peptides and multimeric constructs have been developed to improve binding affinity and tumor retention.